Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.
about
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapyPhysiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeuticsQuantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessmentsPharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeysThe placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation.A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development.Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens.Pharmacokinetics and pharmacodynamics of CD4-anchoring bi-functional fusion inhibitor in monkeys.
P2860
Q28257521-32B3382B-E548-42C1-B75B-C87785AF7C69Q34275537-E3C1F68A-BB4D-4997-A6F1-847FC52C808AQ35192878-63915A47-E4DF-49F2-B425-8FE103BDB7F0Q35840838-B96FBF72-1985-496E-A1E1-3B6726482265Q35929084-371B30FA-C311-4E06-A5E1-D45683316BDFQ36331552-F70414CD-54EC-4D2E-A745-AE41D0A023F9Q37141605-0F4C24F2-C8E1-4D0E-8833-5FA2466D24A9Q37986126-F986E5AC-B337-4417-B877-A910A92B1DAEQ38072598-B6BE635C-2F12-4CE1-A92F-565864C9DA45Q38728589-D980D826-EB07-4A70-BE70-22AB17D11354Q40703054-05946AB6-A531-40F3-968A-06C40FFDA6F2Q41104888-9BBA5753-EF02-4260-BEEB-42610BD5D9CEQ42186438-91AA29DC-B861-4EFA-A905-A4111B13233BQ44779448-0E3FFF35-FD2A-4E80-9EAC-E74900115BACQ46188788-253F4226-D156-4BE8-BC80-11D41035D7B5
P2860
Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Translational pharmacokinetics ...... inical model to phase I study.
@en
Translational pharmacokinetics ...... inical model to phase I study.
@nl
type
label
Translational pharmacokinetics ...... inical model to phase I study.
@en
Translational pharmacokinetics ...... inical model to phase I study.
@nl
prefLabel
Translational pharmacokinetics ...... inical model to phase I study.
@en
Translational pharmacokinetics ...... inical model to phase I study.
@nl
P2093
P2860
P356
P1476
Translational pharmacokinetics ...... inical model to phase I study.
@en
P2093
E G Stefanich
H Scheerens
P J Fielder
S K Fischer
P2860
P304
P356
10.1038/CLPT.2010.311
P407
P577
2010-12-29T00:00:00Z